1.57
전일 마감가:
$1.66
열려 있는:
$1.66
하루 거래량:
807.00K
Relative Volume:
0.50
시가총액:
$70.53M
수익:
-
순이익/손실:
$-97.22M
주가수익비율:
-1.1377
EPS:
-1.38
순현금흐름:
$-82.44M
1주 성능:
+9.03%
1개월 성능:
-17.37%
6개월 성능:
-94.09%
1년 성능:
-92.77%
카사바 Stock (SAVA) Company Profile
명칭
Cassava Sciences Inc
전화
512-501-2444
주소
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
SAVA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SAVA
Cassava Sciences Inc
|
1.57 | 70.53M | 0 | -97.22M | -82.44M | -1.38 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
카사바 Stock (SAVA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-11-26 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2024-10-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2024-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2022-11-16 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
2021-07-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2021-07-07 | 재확인 | Maxim Group | Buy |
2021-04-27 | 개시 | B. Riley Securities | Buy |
2021-02-16 | 재확인 | H.C. Wainwright | Buy |
2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
2020-09-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2020-05-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2020-05-15 | 다운그레이드 | Maxim Group | Buy → Hold |
2020-01-10 | 재확인 | Maxim Group | Buy |
모두보기
카사바 주식(SAVA)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Cassava Sciences (SAVA) Announces Leadership Change Amid Future Strategy Plans - GuruFocus
Cassava Sciences appoints new SVP of Clinical Development By Investing.com - Investing.com South Africa
Cassava Sciences CMO James Kupiec to Retire - marketscreener.com
Cassava chief medical officer to retire - Seeking Alpha
Cassava Sciences Announces Leadership Changes Amid Strategic Shift - TipRanks
Cassava Sciences appoints new SVP of Clinical Development - Investing.com
Cassava Announces Retirement of Chief Medical Officer, Dr. - GlobeNewswire
Cassava Sciences Pivots Beyond Alzheimer's: New Leadership Eyes Breakthrough in Rare Disease Treatment - Stock Titan
Investigation announced for Long-Term Investors in Cassava - openPR.com
Cassava Sciences, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsSAVA - ACCESS Newswire
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study - MSN
SAVA Stock Plummets to 52-Week Low at $1.16 Amid Market Struggles By Investing.com - Investing.com South Africa
SAVA Stock Plummets to 52-Week Low at $1.16 Amid Market Struggles - Investing.com Australia
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Stockholders to Connect - ACCESS Newswire
SAVA stock touches 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
SAVA stock touches 52-week low at $1.34 amid market challenges - Investing.com Australia
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround - Yahoo Finance
After Two Phase 3 Trial Fails, Cassava Sciences Gives Up On Alzheimer’s Drugs - Being Patient
Is the Future Bleak for SAVA Stock Following Another Setback? - Nasdaq
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug - MSN
Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful - MSN
Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus - MSN
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer’s drug By Reuters - Investing.com
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Zacks Investment Research
Cassava ends Alzheimer’s program after simufilam fails again - The Pharma Letter
Cassava ends simufilam Alzheimer’s programme after second Phase III failure - Yahoo Finance
카사바 (SAVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
카사바 주식 (SAVA) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
1.18 |
50,000 |
59,000 |
71,300 |
Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.86 |
59,800 |
230,828 |
11,500 |
Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.82 |
2,000 |
7,640 |
0 |
자본화:
|
볼륨(24시간):